颈动脉血运重建术后脑过度灌注综合征的危险因素
基于血管质量倡议(VQI)数据库2015—2021年156003例颈动脉血运重建手术的分析显示,颈动脉内膜切除术(CEA)、经颈动脉血运重建术(TCAR)和经股动脉颈动脉支架置入术(TFCAS)术后脑过度灌注综合征(CHS)发生率分别为0.15%、0.18%和0.53%;TCAR和TFCAS与CEA相比CHS风险无显著差异。既往短暂性脑缺血发作或卒中史、48小时内紧急干预、完全闭塞病变及术后需静脉降压药物与CHS风险升高相关;出院时使用血管紧张素转换酶抑制剂或血管紧张素II受体拮抗剂与CHS风险降低相关。
要点
- CEA、TCAR和TFCAS术后CHS发生率分别为0.15%、0.18%和0.53%。
- TCAR和TFCAS与CEA相比,CHS风险无显著差异。
- 既往TIA或卒中史、紧急干预、完全闭塞病变及术后静脉降压药物与CHS风险升高相关。
核心结论
- 与CEA相比,TCAR和TFCAS与术后CHS风险增加无统计学关联。
- 既往TIA或卒中史、需紧急干预或术后静脉降压药物、或因完全闭塞接受治疗的患者发生CHS的风险更高。
- 出院时使用ACEI/ARB似乎对CHS有保护作用,应考虑用于最高风险患者。
研究设计与样本
- 研究查询了血管外科学会血管质量倡议(VQI)数据库中2015—2021年接受CEA、TCAR或TFCAS的年龄≥18岁患者,排除急诊手术。
- 共纳入156003例手术,其中CEA占72.7%,TCAR占12.4%,TFCAS占14.9%。
- 主要结局为术后发生CHS,定义为术后癫痫发作、过度灌注所致脑出血或两者兼有。
- 采用双变量和多变量逻辑回归分析识别与CHS相关的因素。
主要发现
- CEA、TCAR和TFCAS术后CHS发生率分别为0.15%、0.18%和0.53%。
- TFCAS与CEA相比CHS风险无显著差异(OR 1.21;95%CI 0.76-1.92;P=0.416)。
- TCAR与CEA相比CHS风险无显著差异(OR 0.91;95%CI 0.57-1.45;P=0.691)。
- 与CHS风险升高相关的围手术期因素包括:既往TIA或卒中史(OR 2.50;95%CI 1.69-3.68;P<0.0001)、48小时内需紧急干预(OR 2.03;95%CI 1.43-2.89;P<0.0001)、治疗完全闭塞(OR 3.80;95%CI 1.16-12.47;P=0.028)、术后需静脉降压药物(OR 5.45;95%CI 3.97-7.48;P<0.0001)。
- 年龄、术前高血压、同侧狭窄程度≤99%及既往颈动脉手术史与CHS风险增加无统计学关联。
关键数值与推荐
- CHS定义为术后癫痫发作、过度灌注所致脑出血或两者兼有。
- TCAR与CEA相比CHS风险无显著差异(OR 0.91;95%CI 0.57-1.45;P=0.691)。
- TFCAS与CEA相比CHS风险无显著差异(OR 1.21;95%CI 0.76-1.92;P=0.416)。
- 出院时使用ACEI或ARB与CHS风险降低相关(OR 0.47;95%CI 0.34-0.65;P<0.0001)。
临床怎么用
- 作者认为,出院时使用ACEI/ARB似乎对CHS有保护作用,应考虑用于最高风险患者。
- 对于既往TIA或卒中史、需紧急干预、术后需静脉降压药物或治疗完全闭塞的患者,应认识到其CHS风险较高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cerebral hyperperfusion syndrome (CHS) is a rare but known complication of carotid revascularization that can result in severe postoperative disability and death. CHS is a well-described sequela of carotid endarterectomy (CEA) and, more recently, of transfemoral carotid artery stenting (TFCAS), but its incidence after transcarotid artery revascularization (TCAR) has not been delineated. The aims of this study were to determine the impact of procedure type (CEA versus TCAR versus TFCAS) on the development of CHS as well as to identify perioperative risk factors associated with CHS. METHODS: The Society for Vascular Surgery Vascular Quality Initiative was queried for patients aged ≥18 years who underwent CEA, TCAR, or TFCAS from 2015-2021. Emergent procedures were excluded. The primary outcome was postoperative development of CHS, defined as the presence of postoperative seizures, intracerebral hemorrhage due to hyperperfusion, or both. Bivariate and multivariable logistic regression analyses were performed to identify factors associated with CHS. RESULTS: 156,003 procedures were included (72.7% CEA, 12.4% TCAR, and 14.9% TFCAS). The incidence of CHS after CEA, TCAR, and TFCAS were 0.15%, 0.18%, and 0.53%, respectively. There was no significant difference in risk of CHS after TFCAS compared to CEA (odds ratio [OR]: 1.21; 95% confidence interval [CI] 0.76-1.92; P = 0.416), nor was there a difference between TCAR and CEA (OR: 0.91; 95% CI 0.57-1.45; P = 0.691). Perioperative risk factors associated with an increased risk of CHS included previous history of transient ischemic attack or stroke (OR: 2.50; 95% CI 1.69-3.68; P < 0.0001), necessity for urgent intervention within 48 hr (OR: 2.03; 95% CI 1.43-2.89; P < 0.0001), treatment of a total occlusion (OR: 3.80; 95% CI 1.16-12.47; P = 0.028), and need for postoperative intravenous blood pressure medication (OR: 5.45; 95% CI 3.97-7.48; P < 0.0001). Age, preoperative hypertension, degree of ipsilateral stenosis less than or equal to 99%, and history of prior carotid procedures were not statistically associated with an increased risk of CHS. Discharging patients on an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker was associated with a decreased risk of developing CHS (OR: 0.47; 95% CI 0.34-0.65; P < 0.0001). CONCLUSIONS: Compared with CEA, TCAR and TFCAS were not statistically associated with an increased risk of postoperative CHS. Patients with a previous history of transient ischemic attack or stroke, who require urgent intervention or postoperative intravenous blood pressure medication, or who are treated for a total occlusion are at a higher risk of developing CHS. Using an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker on discharge appears to be protective against CHS and should be considered for the highest risk patients.
引用
- Hsu AC, Williams B, Ding L, et al. Risk Factors for Cerebral Hyperperfusion Syndrome following Carotid Revascularization. Ann Vasc Surg. 2023. PMID: 37356658. doi:10.1016/j.avsg.2023.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。